33rd Annual CFS™ Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®
Past Events

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 23.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


CONTINUING EDUCATION CREDIT (Pharmacists, Nurses, Nurse Practitioners, and Physician Assistants):
You will receive a certificate of attendance for the CME-certified sessions (those designated for AMA/PRA Category 1 Credits™) which may be submitted to state licensing boards for determination of credit reciprocity (conversion to CEUs).

Acknowledgment of Commercial Support

This activity is supported by educational grants from Astellas, AstraZeneca, Boston Biomedical Pharma, Inc., Celgene Corporation, Clovis Oncology, Eisai Inc., Exelixis, Incyte Corporation, Ipsen Biopharmaceuticals, Inc., Lilly, Merck & Co., Inc., Merrimack Pharmaceuticals, Nektar Therapeutics, Novartis Pharmaceuticals Corporation, Novocure, Pharmacyclics, Inc. and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Puma Biotechnology, Taiho Oncology, Inc., and Takeda Oncology.

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

The CFS™ Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® is wholly owned and operated by PER Events, LLC, an affiliate of Physicians' Education Resource®.
33rd Annual CFS™ Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®


Thursday, November 5, 2015
6:00 PM - 7:30 PM
Independent CME-Certified Ancillary Satellite Symposium
The Biosimilar Era: Opportunities and Considerations
Julliard Complex, Level 5

Friday, November 6, 2015
1:30 PM - 3:00 PM
CME-Certified Concurrent Symposium - Live Taping of Medical Crossfire®:
Mutational Testing Through Multiple Lines of NSCLC Therapy

Sky Lobby, Level 16




The Biosimilar Era: Opportunities and Considerations

Thursday, November 5, 2015
6:00 PM - 7:30 PM
New York Marriott Marquis
Julliard - Floor 5
1535 Broadway
New York, NY 10036

Overview

This live symposium is specifically designed to address educational gaps regarding biologics and biosimilars for the treatment of patients with cancer. The engaging program will feature experts in the field discussing challenging questions via educational presentations and faculty panel discussion, highlighting the most up-to-date information regarding the development and approval of biosimilars. Through the use of informative presentations, interactive panel commentaries, and audience question and answer sessions, participants will be able to receive valuable insight and interact directly with the experts.

Target Audience

This educational activity is specifically designed to meet the needs of medical oncologists, hematologists, and other healthcare professionals involved in the treatment of patients with cancer in the United States.

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Identify how biosimilars differ from other medicines in terms of their structure, function, and development pathway
  • Describe key clinical considerations associated with the use of biosimilars in oncology, including extrapolation, immunogenicity, pharmacovigilance, and patient communication
  • Evaluate the historic experience and recent clinical trial data regarding the safety and efficacy of biosimilars for cancer care

Accreditation/Credit Designation

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

prIME Oncology designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is provided by prIME Oncology.

Acknowledgment of Commercial Support

This educational activity is supported by a grant from Hospira, Inc., a Pfizer Company.
 



CME-Certified Concurrent Symposium - Live Taping of Medical Crossfire®: Mutational Testing Through Multiple Lines of NSCLC Therapy

Friday, November 6, 2015
1:30 PM - 3:00 PM
Sky Lobby, Level 16
1535 Broadway
New York, NY 10036

Overview

This activity aims to update oncology healthcare professionals who participate in the multidisciplinary treatment of patients with lung cancers by providing expert guidance, interpretation, and opinions on the importance and impact of EGFR and molecular testing through multiple lines of therapy, as well as emerging technologies that can assist in this regard.

This will be a 3-module Medical Crossfire® panel discussion, highlighting the expert exchange of ideas and best practices regarding the impact of mutational testing throughout the lung cancer treatment paradigm. Module 1 will be mostly didactic in nature, with discussion of needs and ways to overcome barriers to optimal testing. Modules 2 and 3 will be case-based discussions and interpretations in the setting of EGFR mutated NSCLC along the continuum of disease.

Target Audience

This educational activity is directed toward medical oncologists, pulmonologists, pathologists, and radiologists who treat patients with lung cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of lung cancer may also participate.

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Explain how to personalize treatment strategies for patients with advanced forms of lung cancer based on individual tumor characteristics
  • Describe evolving strategies to personalize treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC)
  • Explain the importance of proper tissue acquisition to aid in the decision-making process in the context of identifying actionable mutations in lung cancer
  • Explain current and emerging technologies to monitor resistance and tumor heterogeneity in lung cancer, including evidence concerning the use of liquid biopsies to monitor resistance clones along the disease continuum
  • Apply a multidisciplinary approach to facilitate and optimize tumor tissue testing in the setting of advanced NSCLC, and manage cases in multiple lines of care

Program Chair

Mark G. Kris, MD
Attending Physician, Thoracic Oncology Service
William and Joy Ruane Chair in Thoracic Oncology
Memorial Sloan-Kettering Cancer Center
New York, NY


Accreditation/Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from AstraZeneca.


 

Free Registration for Pharmicists registering for CFS™. Directions in Oncology Pharmacy.

Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
2627282930
Filter By